Moderna’s seasonal influenza vaccine, mRNA-1010, succeeded in a large Phase 3 trial demonstrating a 26.6% relative efficacy advantage over standard-dose licensed flu vaccines in adults aged 50 and above. The data showed strong protection against all included influenza strains, with a safety profile comparable to existing vaccines. This success enables Moderna to advance FDA discussions, potentially bringing the first mRNA-based flu vaccine to U.S. markets for the 2026-2027 season and reopening prospects for a combined COVID-flu shot. The development marks a revitalization of Moderna’s vaccine pipeline amidst challenges in its COVID booster uptake and RSV vaccine growth.